Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

The biotech IPO market continues to produce outsized debuts. Parabilis setting terms at up to $475M would make it the year's second-largest IPO behind Kailera ($625M). The company raised more than $700M in private funding before filing, making it the fifth biotech to IPO in 2026 after exceeding that private funding threshold. Total 2026 biotech IPO proceeds already surpass $3.2B. The Parabilis IPO is notable because it comes just weeks after the company signed its Regeneron partnership. Investors are paying for a validated platform (Antibody-Helicon Conjugates) with a major pharma partner already on board. Meanwhile, the Roche chairman's "blackmail" comment is the most direct public criticism of U.S. tariff policy by a sitting pharma executive this year. Schwan said the MFN deal was signed under pressure. His candor reflects a growing tension in the industry: companies are signing deals and pledging investments to avoid tariffs while privately resenting the framework. On the AI front, Alnylam joining forces with Inceptive adds another data point to the AI drug discovery buildout. Alnylam is using AI to optimize RNAi therapeutics, specifically to prioritize the best siRNA sequences from a massive design space. This is different from the Anthropic approach (broad drug design) or the Isomorphic approach (protein structure prediction) and underscores that AI adoption in pharma is not one-size-fits-all. 👉 Read Full Analysis

🔮 What To Watch

🏢 Corporate & Capital Markets

Parabilis Sets Terms for Up to $475M IPO

Parabilis Medicines set terms for an IPO that would raise as much as $475M, according to BioPharma Dive, ranking it as the year's second-largest new biotech stock offering behind Kailera's $625M debut in April. Parabilis is developing Antibody-Helicon Conjugates (AHCs), a novel therapeutic class, and signed a strategic research collaboration with Regeneron last month. The company raised more than $700M in private funding before filing. BioPharma Dive noted Parabilis would be the fifth biotech to IPO in 2026 after raising $700M or more in private funding.

Chinese Biotechs Commanding Higher Premiums

BioSpace reported that deal dynamics between Chinese biotechs and global pharma companies are changing fast. Chinese companies are no longer a "bargain pool" and are commanding higher upfront payments. Western buyers are responding by seeking more expansive platform deals (BMS/Hengrui 13 programs, Pfizer/Innovent 12 programs, Lilly/Haisco 5 programs) rather than single-asset licenses. This shift reflects the quality of Chinese clinical-stage assets, demonstrated by Phase 3 wins (sac-TMT, ivonescimab) and ASCO data presentations (Hengrui 90+ studies, Akeso plenary).

🌍 Policy & Geopolitical

Roche Chairman Calls U.S. Tariffs "Blackmail"

Roche chairman Severin Schwan called U.S. tariff policies "blackmail" and described protectionism by the United States and China as the company's biggest geopolitical concern, according to Reuters via Endpoints News. Schwan was specifically asked about the MFN agreement Roche/Genentech signed with the Trump administration. His comments are the most direct public criticism of U.S. pharma tariff policy by a sitting major pharma executive this year. All 17 targeted companies have signed MFN deals, but Schwan's remarks suggest the agreements were made under duress rather than voluntarily.

🔬 Clinical & AI

Alnylam Partners with Inceptive on AI for RNAi Discovery ALNY

Alnylam Pharmaceuticals signed a strategic AI collaboration with Inceptive Nucleics to speed up the discovery of RNA interference therapies under its Alnylam 2030 strategy, according to The Pharma Letter. Inceptive's AI platform helps optimize siRNA sequence design and selection, potentially accelerating the identification of lead candidates from Alnylam's pipeline targets. This adds to the growing AI drug discovery ecosystem: Anthropic (BMS, Sanofi, Novo, AbbVie, Novartis), Isomorphic Labs ($2.7B, Lilly/Novartis), Profluent (Lilly, $2.25B), and now Inceptive (Alnylam).

Biogen Gets Breakthrough Therapy for SMA Drug BIIB

Biogen received FDA Breakthrough Therapy designation for salanersen, an investigational antisense oligonucleotide for spinal muscular atrophy, according to The Pharma Letter. The designation recognizes preliminary clinical evidence suggesting salanersen may offer substantial improvement over existing therapies. Biogen already markets Spinraza for SMA but has faced competition from Novartis's Zolgensma (gene therapy) and Roche's Evrysdi (oral). A next-generation SMA treatment could reinvigorate Biogen's neuroscience franchise.

📋 The Week in Review

📅 The Week Ahead

The AI drug discovery landscape is no longer monolithic. Different platforms serve different pharma needs:

Anthropic (Claude): Broad AI platform applied across drug development workflows. Partners: BMS, Sanofi, Novo Nordisk, AbbVie, Novartis (board seat). Acquired Coefficient Bio ($400M) for in-house biology. Gates Foundation partnership for global health.

Isomorphic Labs: Protein structure prediction and molecular design derived from AlphaFold. $2.7B in total funding. Partners: Lilly, Novartis. Focused on target identification and lead optimization.

Profluent Bio: AI-designed recombinases for kilobase-scale DNA editing. Lilly collaboration ($2.25B milestones). Focused on gene editing and genetic medicine.

Inceptive Nucleics: AI optimization of RNA sequences for RNAi therapeutics. Alnylam partnership. Focused on siRNA design and candidate selection.

Recursion Pharmaceuticals: Operating system for drug discovery combining biology, chemistry, and computation. Multiple pharma partnerships. Public company.

Each serves a distinct need: broad workflow AI, protein design, gene editing, RNA optimization, and integrated discovery. The companies using AI most effectively are the ones matching the right platform to the right problem.

💊 China Premium Shift

BioSpace's reporting on Chinese biotechs "commanding higher premiums" reflects a fundamental market maturation. In 2023 and 2024, Western pharma could license Chinese clinical-stage assets at relatively modest upfronts because Chinese biotechs needed cash and lacked global commercial infrastructure. In 2026, the dynamic has shifted:

For BD teams: the China licensing window is still open, but the economics have shifted toward the licensors. Early-mover advantages (Merck/Kelun-Biotech, Lilly/Hengrui) captured the best value. Later entrants (Pfizer/Innovent at $10.5B) are paying more per program.

📊 H1 2026 Final Scorecard

As we enter the second half of June, the first-half numbers are essentially final:

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →